Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder

被引:158
|
作者
Mota-Pereira, Jorge [1 ,2 ]
Silverio, Jorge [2 ]
Carvalho, Serafim [1 ]
Ribeiro, Jose Carlos [3 ]
Fonte, Daniela [4 ]
Ramos, Joaquim [5 ]
机构
[1] Hosp Magalhaes Lemos, Porto Psychiat Dept, P-4149003 Oporto, Portugal
[2] Univ Minho, Sch Psychol, P-4719 Braga, Portugal
[3] Univ Porto, Fac Sports, Res Ctr Phys Act Hlth & Leisure, Oporto, Portugal
[4] Hosp Sao Joao, Dept Radiotherapy, Oporto, Portugal
[5] Hosp Magalhaes Lemos, Psychosocial Rehabil Dept, P-4149003 Oporto, Portugal
关键词
Exercise; Major depressive disorder; MDD; Treatment-resistant; COMPUTER-SCIENCE; HEALTH; CALIBRATION; MANAGEMENT; SYMPTOMS; DISEASE; ADULTS;
D O I
10.1016/j.jpsychires.2011.02.005
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
4Background: Treatment-resistant major depressive disorder (MDD) is a complex condition, with very low remission rates. Physical exercise has been used, with some encouraging results, as an alternative therapy in other depressive disorders. This study assessed the impact on depression and functioning parameters of a moderate intensity exercise program, as an adjuvant to pharmacotherapy, in treatment-resistant MDD patients. Methods: 150 individuals with treatment-resistant MDD, defined as taking combined therapy in doses considered adequate for 9-15 months, without showing clinical remission, were initially screened. 33 were randomized to one of two groups: usual pharmacotherapy (N = 11) and usual pharmacotherapy plus aerobic exercise (N = 22). The exercise program consisted of home-based 30-45 min/day walks, 5 days/week, for 12 weeks, being 1 walk per week supervised. Results: The exercise group showed improvement of all depression and functioning parameters, as indicated by lower HAMD17, BDI and CGI-S and higher GAF (p < 0.05) at last observation compared both to baseline values and to control group. At the end of the study none of the participants in the control group showed response or remission, whilst in the exercise group 21% of participants showed response and 26% remission, although these differences were not statistically significant. Conclusion: A 12 week, home-based exercise program of 30-45 min/day walks, 5 days/week, improved depression and functioning parameters in treatment-resistant MDD patients, and contributed to remission of 26% of these patients. Moderate intensity exercise may be a helpful and effective adjuvant therapy for treatment-resistant MDD. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1005 / 1011
页数:7
相关论文
共 50 条
  • [21] Axis III disorders in treatment-resistant major depressive disorder
    Papakostas, GI
    Petersen, T
    Iosifescu, DV
    Roffi, PA
    Alpert, JE
    Rosenbaum, JE
    Fava, M
    Nierenberg, AA
    PSYCHIATRY RESEARCH, 2003, 118 (02) : 183 - 188
  • [22] Analysis of Cortical Thickness in Treatment-Resistant Major Depressive Disorder
    Phillips, Jennifer L.
    Batten, Lisa A.
    Tremblay, Philippe
    Blier, Pierre
    BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 171S - 171S
  • [23] Use of atypical antipsychotics for treatment-resistant major depressive disorder
    Papakostas G.I.
    Shelton R.C.
    Current Psychiatry Reports, 2008, 10 (6) : 481 - 486
  • [24] The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    Papakostas, GI
    Worthington, JJ
    Iosifescu, DV
    Kinrys, G
    Burns, AM
    Fisher, LB
    Homberger, CH
    Mischoulon, D
    Fava, M
    DEPRESSION AND ANXIETY, 2006, 23 (03) : 178 - 181
  • [25] Treatment-resistant depression: a possible 'inflammatory subtype' of depressive disorder
    Strawbridge, Rebecca
    Young, Allan H.
    Cleare, Anthony J.
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 254 : 152 - 153
  • [26] MODERATE EXERCISE IMPROVES QUALITY OF LIFE IN PATIENTS WITH NON-REMITTED MAJOR DEPRESSIVE DISORDER
    Mota Pereira, J.
    Silverio, J.
    Carvalho, S.
    Ribeiro, J. C.
    Fonte, D.
    Saavedra, I.
    Ribeiro da Silva, M. H.
    Ramos, J.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [27] Olanzapine/FluoxetineA Review of its Use in Patients With Treatment-Resistant Major Depressive Disorder
    Jamie D. Croxtall
    Lesley J. Scott
    CNS Drugs, 2010, 24 : 245 - 262
  • [28] Olanzapine/Fluiloxietine A Review of its Use in Patients With Treatment-Resistant Major Depressive Disorder
    Croxtall, Jamie D.
    Scott, Lesley J.
    CNS DRUGS, 2010, 24 (03) : 245 - 262
  • [29] Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
    Moser, Sarah Sharman
    Chodick, Gabriel
    Gelerstein, Shulamit
    Ben David, Nava Barit
    Shalev, Varda
    Stein-Reisner, Orit
    BMC PSYCHIATRY, 2022, 22 (01)
  • [30] Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
    Sarah Sharman Moser
    Gabriel Chodick
    Shulamit Gelerstein
    Nava Barit Ben David
    Varda Shalev
    Orit Stein-Reisner
    BMC Psychiatry, 22